

Short Communication

Cite this article: Mebius MM *et al* (2020). Haemostatic changes in urogenital schistosomiasis haematobium: a case-control study in Gabonese schoolchildren. *Journal of Helminthology* **94**, e84, 1–6. <https://doi.org/10.1017/S0022149X19000798>

Received: 18 May 2019
Revised: 30 July 2019
Accepted: 1 August 2019


Key words:

Schistosomiasis haematobium; haemostasis; von Willebrand Factor; osteoprotegerin; endothelial activation

Author for correspondence:

J.J. van Hellemond, E-mail: j.vanhellemond@erasmusmc.nl

Haemostatic changes in urogenital schistosomiasis haematobium: a case-control study in Gabonese schoolchildren

M.M. Mebius^{1,2}, A.A. Adegnika^{3,4,5}, J.F. Zinsou^{3,4}, J.C.D. Agobe^{3,4},
Y.J. Honkpehedji^{3,4,5}, M. Yazdanbakhsh⁵, G.J. van Dam⁵, P.L.A.M. Corstjens⁶,
A.G.M. Tielens^{1,7}, P.G. de Groot², R.T. Urbanus² and J.J. van Hellemond¹ 

¹Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands; ²Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands; ³Centre de Recherches Médicales de Lambaréné (CERMEL), BP 118 Lambaréné, Gabon; ⁴Institut für Tropenmedizin, Universität Tübingen, Tübingen, Germany; ⁵Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands; ⁶Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands and ⁷Department of Biochemistry and Cell Biology, Faculty Veterinary Medicine, Utrecht University, The Netherlands

Abstract

In many tropical areas schistosomiasis is a major health problem causing hepatosplenic, intestinal or urogenital complaints. Hepatosplenic schistosomiasis mansoni is also characterized by blood coagulation abnormalities. Liver pathology plays a role in the development of haemostatic changes and the parasitic infection may directly affect coagulation. However, these contributing factors cannot be studied separately in hepatosplenic schistosomiasis infections. This pilot study provides insight in haemostatic changes in urinary schistosomiasis by studying coagulation parameters in schistosomiasis haematobium-infected Gabonese schoolchildren. Selection on urinary schistosomiasis patients without hepatosplenic complaints allows for the investigation of the direct effects of the parasite on haemostasis. Levels of von Willebrand Factor (VWF) antigen, active VWF and osteoprotegerin were elevated, indicating inflammation-mediated endothelial activation. In contrast to hepatosplenic schistosomiasis, thrombin–antithrombin complex and D-dimer levels were not affected. Despite its small sample size, this study clearly indicates that *Schistosoma haematobium* directly alters the activation status of the endothelium, without initiation of coagulation.

Introduction

The tropical disease schistosomiasis is caused by blood-dwelling parasites of the *Schistosoma* genus. The major disease-causing species in humans are *Schistosoma mansoni*, *Schistosoma haematobium* and *Schistosoma japonicum* (Colley *et al.*, 2014). With almost 800 million people at risk of infection, schistosomiasis is the second major parasitic disease after malaria (Steinmann *et al.*, 2006).

The various species of *Schistosoma* reside in blood vessels at different locations in the body, and these specific locations determine pathology. *Schistosoma mansoni* and *S. japonicum* reside in the mesenteric plexus, and chronic infection results in the development of intestinal or hepatosplenic schistosomiasis, affecting intestine, liver and spleen (Colley *et al.*, 2014). In contrast, *S. haematobium* resides in the perivesicular plexus. Infection with this species results in urogenital schistosomiasis, affecting mainly the urogenital tract, although hepatic disease may occur in severe infections (Cheever *et al.*, 1977; Colley *et al.*, 2014).

In addition to intestinal and hepatic disease, the blood coagulation system is affected in schistosomiasis mansoni patients (Mebius *et al.*, 2013). These individuals are prone to bleeding as a result of coagulation-factor deficiencies, and often have reduced platelet counts (reviewed by Tanabe, 2003). Several factors are presumed to contribute to the loss of coagulation factors and platelets. First, the consumption of coagulation factors through the continuous activation of coagulation may be involved, since markers of active coagulation, such as thrombin–antithrombin (TAT) complexes, and markers of fibrinolysis, such as D-dimers, are both elevated in these patients. This activation of coagulation can be induced by the parasite itself, but it is also assumed that immune responses to schistosomes play a role in the development of haemostatic abnormalities in hepatosplenic schistosomiasis mansoni – for example, through stimulation of monocyte-tissue-factor expression (Amer & Amer, 2002). Second, the majority of coagulation factors are synthesized by the liver. Therefore, impaired liver function, resulting in reduced hepatic synthesis or clearance of activated coagulation factors, could contribute to the bleeding phenotype. It remains challenging to unravel the contribution of the parasite and liver damage

to the development of haemostatic abnormalities in hepatosplenic schistosomiasis *mansoni* patients, since these factors cannot be separated in hepatosplenic disease.

This pilot study aims to elucidate the contribution of the parasite to the development of coagulation abnormalities in *Schistosoma* infections by studying haemostatic parameters in schoolchildren infected with *S. haematobium*. Since *S. haematobium* infections primarily cause urogenital schistosomiasis, strict selection on *S. haematobium*-infected individuals without hepatosplenomegaly limits the influence of impaired hepatic function and allows investigation of the effect of only the parasitic infection on the development of coagulation abnormalities.

Materials and methods

Participants and sample collection

Ten schoolchildren with non-hepatosplenic schistosomiasis *haematobium* and four healthy controls without *S. haematobium* infection were recruited at the Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon. The study was approved by the CERMEL Institutional Ethics Committee (CEI, CEI-MRU 002 26/1/2016). Participants were schoolchildren without hepatosplenic complaints from Zilé-PK15 areas – *S. haematobium*-endemic areas surrounding Lambaréné (Ateba Ngoa *et al.*, 2014). The presence of possible asymptomatic other infectious diseases that could affect haemostasis, such as malaria, were not investigated, but if present among the included participants these asymptomatic infections are expected to be evenly distributed between participants with and without urinary schistosomiasis. Informed consent was obtained from the parents or legal guardians of all children, and all infected individuals received treatment with praziquantel after sample collection. Venous blood was collected in a tube containing 1:10 volume of anticoagulant 3.2% sodium citrate solution. Whole blood was analysed with the Pentra 60 analyser (Horiba, Kyoto, Japan). Citrated platelet-poor plasma was obtained by twofold centrifugation of citrated blood at 2000×g for 15 min. Citrated plasma was aliquoted and stored at –80°C.

Determination of *S. haematobium* infection

Circulating anodic antigen (CAA) levels were determined in 20 µl citrated plasma with the wet reagent SCAA20 (standard serum/plasma CAA test on 20 µl trichloroacetic acid (TCA) extract) lateral flow assay, as described by Corstjens *et al.* (2014). Samples were treated with 4% TCA to remove interfering components. CAA levels were calculated with a four-parametric curve-fitting method, using a standard dilution curve of the TCA-soluble fraction of schistosome adult worm antigen (AWA-TCA), which contains approximately 3% (w/w) CAA. The lower detection limit of the SCAA20 was 150 pg/ml AWA-TCA (=5 pg CAA/ml). Participants were considered positive when CAA levels were above 5 pg/ml. In addition, for all participants a midstream urine sample was collected during the daytime and at least 10 ml urine was passed through a 12.0 µm polyamide N-filter (Millipore, Billerica, MA, USA). *Schistosoma haematobium* eggs were detected by microscopic examination.

Enzyme-linked immunosorbent assay

Levels of D-dimer were measured in plasma with the Technozym D-dimer ELISA kit (Stago BNL, Leiden, The Netherlands)

according to the manufacturer's instructions. Levels of von Willebrand Factor (VWF) antigen (VWF:ag), active VWF, ADAMTS-13 antigen (ADAMTS-13:ag), osteoprotegerin (OPG) and TAT complexes were measured in plasma with ELISA. Ninety-six-well or 384-well white Maxisorp microtiter plates (Thermo Scientific, Roskilde, Denmark) were coated overnight at 4°C with polyclonal rabbit-anti-human VWF (0.775 µg/ml; A0082; DAKO, Carpinteria, CA, USA), AU/VWf-11 nanobody (Hulstein *et al.*, 2005) (1.98 µg/ml), D053 (0.5 µg/ml; Sanquin, Amsterdam, The Netherlands), mouse-anti-human OPG/TNFRSF11B (1 µg/ml; R&D Systems, Minneapolis, MN, USA) or sheep-anti-human Thrombin (1 µg/ml; Stago BNL, Leiden, The Netherlands) in coating buffer (40 mM sodium carbonate, 35 mM sodium bicarbonate, 3 mM sodium azide, pH 9.6). Plates were washed four times with washing buffer (phosphate-buffered saline (PBS; ThermoFisher Scientific, Waltham, MA, USA), 0.05% Tween20, pH 7.4) between all incubation steps, and blocked for one hour at room temperature with blocking buffer (PBS, 1% bovine serum albumin (BSA), pH 7.4). Citrated plasma and standards were diluted in blocking buffer: 125-fold for VWF:ag ELISA, five- and tenfold for active VWF ELISA, 40-fold for ADAMTS-13:ag ELISA and fourfold for OPG and TAT ELISAs, and incubated for one hour at room temperature. Used standards were serial dilutions of normal pooled plasma (Sanquin, Amsterdam, The Netherlands) with a known concentration of VWF:ag for VWF:ag and ADAMTS-13:ag, normal pooled serum with known concentrations of TAT and OPG for TAT and OPG ELISAs and VWF-depleted plasma (Affinity Biologicals, Ancaster, Canada) supplemented with recombinant R1341Q-VWF for active VWF ELISA. Following sample incubation, the plates were incubated at room temperature for one hour with the following detection and secondary antibodies diluted in blocking buffer: peroxidase-conjugated rabbit-anti-human VWF (0.325 µg/ml), peroxidase-conjugated rabbit-anti-human VWF (1.2 µg/ml), biotinylated polyclonal sheep-anti-human ADAMTS-13 (0.25 µg/ml; R&D Systems, Minneapolis, MN, USA) and streptavidin-mono-horseradish peroxidase (HRP) (0.83 µg/ml; DAKO, Carpinteria, CA, USA), biotinylated goat-anti-human OPG/TNFRSF11B (100 ng/ml; R&D Systems, Minneapolis, MN, USA) and streptavidin-mono-HRP (0.25 µg/ml), and peroxidase-conjugated sheep-anti-human antithrombin (0.5 µg/ml; Stago BNL, Leiden, The Netherlands). ELISAs were developed with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific, Waltham, MA, USA) and luminescence was detected with the Synergy2 ELISA reader (BioTek, Winooski, VT, USA). Antigen concentrations were calculated with a five-parametric curve-fitting method, using a dilution curve of the standard. The lower detection limits of the ELISAs were: 6.8 ng/ml (VWF:ag), 16 ng/ml (active VWF), 1.6% (ADAMTS-13:ag), 10.6 pg/ml (OPG) and 2.8 pM (TAT).

Ristocetin co-factor activity assay

Citrated plasma was diluted sevenfold in imidazole buffer (100 mM imidazole, 100 mM NaCl, pH 7.4). A standard dilution curve was prepared of diluted normal pooled plasma. Then, 200 µl BC von Willebrand Reagent (Siemens Healthcare, Erlangen, Germany) was added to the 70 µl sample in a 96-well clear Maxisorp microtiter plate. Following 10 min incubation at 37°C and 20 min incubation at room temperature, to allow platelet aggregates to precipitate, 100 µl of the mixture was transferred to a new plate and non-aggregated platelets were measured at

Table 1. Participant characteristics.

	<i>Schistosoma haematobium</i> -infected children	Controls
Number, <i>n</i>	10	4
Age (y), mean (SD)	11 (3)	8 (1)
Male, <i>n</i> (%)	5/10 (50)	3/4 (75)
Weight (kg), mean (SD)	37 (13)	27 (2)
Height (m), mean (SD)	1.47 (0.16)	1.34 (0.03)
CAA (pg/ml), mean (SD)	2166 (3062)	0 (0)
Egg count positive, <i>n</i> (%)	9/10 (90)	0/4 (0)
Egg count/10 ml urine, mean (SD)	272 (289)	0 (0)
Parasitic co-infections, <i>n</i> (%)		
<i>Ascaris</i>	0/8 (0)	0/3 (0)
<i>Ancylostoma</i>	0/8 (0)	0/3 (0)
<i>Trichuris</i>	3/8 (38)	1/3 (33)
Missing	2	1
Whole blood analysis, mean (SD)		
Haemoglobin (g/dl)	11.0 (1.9)	11.7 (1.3)
Missing	1	0
Platelets ($n \times 10^9/l$)	253 (66)	322 (54)
Missing	1	0
White blood cells ($n \times 10^9/l$)	10.5 (3.5)	10.1 (2.9)
Missing	1	0
Eosinophils ($n \times 10^9/l$)	1.8 (0.8)	1.9 (1.3)
Missing	5	1
Lymphocytes ($n \times 10^9/l$)	4.2 (0.9)	3.6 (0.5)
Missing	1	0
Monocytes ($n \times 10^9/l$)	0.7 (0.2)	0.9 (0.2)
Missing	1	0
Splenomegaly, <i>n</i> (%)	1/9 (11)	0/4 (0)
Missing	1	0
Hepatomegaly, <i>n</i> (%)	0/9 (0)	0/4 (0)
Missing	1	0

Data are number with percentage or mean with SD. CAA, circulating anodic antigen; SD, standard deviation.

350 nm. Ristocetin co-factor activity (VWF:RCo) was calculated with a five-parametric curve-fitting method, using a dilution curve of the standard. The lower detection limit of the assay was 3% VWF:RCo.

ADAMTS-13 activity measurement

ADAMTS-13 activity was measured in a kinetic assay using the fluorescence resonance energy transfer substrate VWF73 (FRETs-VWF73; Peptide Institute, Osaka, Japan) as previously described (Kokame *et al.*, 2005). Samples were tenfold diluted in Tris buffer (5 mM Tris, 25 mM calcium chloride, 0.005% Tween20, pH 6.0). FRETs-VWF73 was added to a final concentration of 2 μ M and fluorescence (λ_{ex} 340 nm, λ_{em} 450 nm) was measured in a 96-well black microtiter plate (Thermo Scientific,

Roskilde, Denmark) every 30 s for one hour at 30°C with a Spectramax M2e device (Molecular Devices, Sunnyvale, CA, USA).

Statistical analysis

Analyses were done using PRISM software (GraphPad, San Diego, CA, USA, version 6.01). Infected and non-infected control groups were compared using the Mann–Whitney *U*-test and $P \leq 0.05$ was considered statistically significant.

Results and discussion

We included ten schoolchildren with schistosomiasis haematobium and four healthy children from *S. haematobium*-endemic,




Fig. 1. Haemostatic parameters in *Schistosoma haematobium*-infected schoolchildren. VWF:ag levels (a), active VWF levels (b), ADAMTS-13:ag levels (e), OPG levels (g), TAT levels (h) and D-dimer levels (i) were measured with ELISA in citrated plasma of *S. haematobium*-infected schoolchildren and non-infected controls. Percentage of active VWF (c) was calculated with the determined active VWF and VWF:ag levels. VWF:RCo (d) was determined with the BC von Willebrand Reagent. ADAMTS-13 activity (f) was determined with the FRETTS-VWF73 assay. Dotted lines indicate normal ranges (a, d) or cut-off values (g-i). Statistical analysis was performed with a Mann-Whitney U-test. $P \leq 0.05$ was considered statistically significant. Abbreviation: ns, not significant.

rural areas surrounding Lambaréné (Gabon) (table 1). Infection status was based on CAA levels in plasma (Corstjens *et al.*, 2014) combined with the detection of viable eggs in urine, since the detection of eggs in urine as the only method to confirm infection has a low sensitivity (Colley *et al.*, 2014). As expected, a positive correlation was found between the number of eggs detected by urine filtration and the concentration of CAA in plasma (not shown). Hepatomegaly was absent in all studied individuals and splenomegaly was absent in nine out of ten infected and in all non-infected individuals; therefore, all infected children were characterized as strictly urogenital schistosomiasis haematobium.

In hepatosplenic schistosomiasis mansoni, levels of VWF:ag are highly elevated and inversely correlate with platelet counts, as patients experience thrombocytopenia (Correia *et al.*, 2009). To determine the effect of *Schistosoma* infection on VWF levels in urinary schistosomiasis, we determined VWF:ag, active VWF and VWF ristocetin cofactor activity (VWF:RCo) in our study participants. VWF is secreted by endothelial cells and circulates in a globular conformation in which the platelet-binding A1-domain is inaccessible (Hulstein *et al.*, 2005). Under blood flow, VWF unfolds and adopts an active platelet-binding conformation (active VWF) that can be detected using the AU/VWFA-11 nanobody (Hulstein *et al.*, 2005). Besides flow,

ristocetin can also be used to unfold VWF and study its binding to platelets (VWF:RCo). Levels of VWF:ag and active VWF were significantly increased in infected children compared to non-infected controls ($P = 0.002$ and $P = 0.004$, respectively; see fig. 1a, b). The elevated VWF:ag levels indicate either increased secretion or reduced breakdown of VWF. The proportion of VWF that is active (percentage of active VWF) is slightly decreased in infected children compared to non-infected individuals, indicating that increased conformational activation of circulating VWF is not responsible for the observed increase in active VWF ($P = 0.024$; fig. 1c). In contrast to increased VWF:ag and active VWF levels, VWF:RCo was low or absent in all individuals ($P = 0.6234$; fig. 1d). As all individuals had normal platelet counts ($(253 \pm 66) \times 10^9/l$ and $(322 \pm 54) \times 10^9/l$ in infected and non-infected individuals, respectively ($P = 0.1063$)) and plasma from Dutch controls showed normal VWF:RCo activity (data not shown), this observation cannot be explained by low platelet counts or poor performance of the VWF:RCo assay. Reduced or absent platelet aggregation on ristocetin in Africans compared to Europeans has been reported previously (Dupuy *et al.*, 1978; Buchanan *et al.*, 1981). Reduced platelet function was attributed to a plasma inhibitor of ristocetin-induced platelet aggregation (Dupuy *et al.*, 1978; Buchanan *et al.*, 1981), though genetic polymorphisms in VWF could also affect the ristocetin-based activity

assay (Flood *et al.*, 2010). It is, however, unclear whether these accounted for the observed low VWF:RCo activity in our study. In summary, in urinary schistosomiasis haematobium, VWF:ag and active VWF levels are elevated and do not correlate with platelet counts as thrombocytopenia is absent.

Changes in levels of VWF:ag and active VWF could reflect defects in the VWF-degrading protease ADAMTS-13 (Hulstein *et al.*, 2005), but could also indicate endothelial activation (Lip & Blann, 1997). To study the functionality of ADAMTS-13, both ADAMTS-13:ag levels and ADAMTS-13 activity were determined. ADAMTS-13:ag levels and ADAMTS-13 activity were normal in both infected and non-infected children ($P = 0.4116$ and $P = 0.5774$, respectively; see fig. 1e, f), so no defects in VWF-degradation are present.

Next, endothelial activation was determined using OPG levels as a marker for inflammation-mediated endothelial activation (Zannettino *et al.*, 2005). OPG is not directly involved in coagulation, as OPG is a cytokine of the TNF receptor superfamily involved in several physiological processes, among which are angiogenesis, osteogenesis and inflammation. Elevated levels of OPG were observed in the *S. haematobium*-infected children versus non-infected controls ($P = 0.036$; fig. 1g, dotted line indicates cut-off value). Simultaneous elevation of both VWF:ag and OPG during schistosomiasis haematobium indicates inflammation-mediated endothelial activation and is in line with the reported co-localization of these markers in endothelial Weibel Palade bodies and their simultaneous secretion upon endothelial cell stimulation (Zannettino *et al.*, 2005).

Several mechanisms may explain activation of the vessel wall. Secretion of OPG is stimulated by the inflammatory cytokines TNF- α and IL-1 β (Zannettino *et al.*, 2005). In hepatosplenic schistosomiasis mansoni patients, TNF- α production by peripheral blood mononuclear cells (PBMC) is elevated and plasma levels of soluble TNF receptor I and II are increased (Mwatha *et al.*, 1998), suggesting the contribution of inflammatory cytokines produced during infection to the observed increased OPG levels. However, no correlation between serum levels of TNF- α and infection status or disease severity is observed in schistosomiasis haematobium (Bustinduy *et al.*, 2015). Passage of schistosome eggs through the vessel wall or egg-derived materials could also induce endothelial activation (File, 1995). Furthermore, endothelial adhesion of adult *S. mansoni* through their ventral sucker could damage the endothelium (Silva *et al.*, 1998) and the presence of the adult worm pair in the small veins could alter blood flow, leading to endothelial activation (Mebius *et al.*, 2013).

The observation that endothelial activation occurs during urinary schistosomiasis is of importance, as elevated levels of VWF, OPG and endothelial activation are associated with thrombosis and cardiovascular disease (Jono *et al.*, 2002; Conway *et al.*, 2003). Ongoing coagulation has been demonstrated in hepatosplenic schistosomiasis mansoni, reflected by increased levels of TAT and D-dimer (Tanabe, 2003). Therefore, we investigated whether the observed endothelial activation in urinary schistosomiasis haematobium results in a procoagulant phenotype in urinary schistosomiasis. In contrast to hepatosplenic schistosomiasis mansoni patients, TAT and D-dimer levels were generally low in our study population and we could not demonstrate differences in urinary schistosomiasis patients compared to the non-infected individuals ($P = 0.4116$ and $P = 0.7524$, respectively; fig. 2h, i, dotted line indicates cut-off value), indicating that there is no ongoing coagulation or fibrinolysis in these individuals. However, five of the infected children had TAT levels above the

normal threshold, without elevated D-dimer levels. Coagulation activation may have occurred in these individuals leading to low-level thrombin activation, followed by subsequent inhibition of the formed thrombin by antithrombin, leading to the formation of TAT without fibrin formation, which explains the absence of D-dimers in these individuals.

Here, we report the first study on the direct effects of *S. haematobium* on haemostatic abnormalities in urinary schistosomiasis haematobium patients without hepatosplenic complaints. Despite the small sample size of this pilot study, our observations indicate that *S. haematobium* directly alters the activation status of the vessel wall. This is not unexpected as the relatively large size of the adult worm pairs in the blood vessel will provoke substantial turbulence and increased shear stress along the vessel wall – processes known to induce endothelial activation (Mebius *et al.*, 2013). In contrast to reports on coagulation abnormalities in hepatosplenic schistosomiasis mansoni, ongoing coagulation and fibrinolysis, which is reflected by elevated levels of TAT and D-dimer, was absent in urinary schistosomiasis patients that thus lack apparent physiological changes in their haemostasis. In schistosomiasis mansoni, the reported coagulopathy may be aggravated as a result of impaired liver function (Tanabe, 2003). The direct effects of the parasite on the vessel wall are also of interest, as endothelial activation and elevated levels of VWF are linked to thrombosis. Therefore, we hypothesize that direct activation of the endothelium by *S. haematobium* may be involved in the initiation of coagulation abnormalities in schistosomiasis. Interestingly, a VWF-cleaving peptidase was recently discovered in *S. mansoni*, which suggests that schistosomes have strategies to counteract endothelial activation and elevated levels of VWF, which are unfavourable for both the parasite and its host, as this can lead to thrombosis (Mebius *et al.*, manuscript in preparation). Larger studies on endothelial activation in schistosomiasis haematobium patients with various disease severities are required to confirm our observations, and to elucidate the mechanisms involved in schistosomal-induced endothelial activation and the consequences of this endothelial activation on haemostasis.

Acknowledgements. The authors thank Claudia J. de Dood for the production of the lateral flow test materials and the excellent analysis of the plasma samples with the SCAA20 assay. The authors also thank the research lab team from CERMEL for their assistance in plasma collection.

Financial support. This work was supported by the Netherlands Organization for Scientific Research (NWO), the Erasmus Postgraduate School Molecular Medicine (MolMed; Erasmus Graduate Programme Infection & Immunity, NWO file number 022.005.032) and by a European and Developing Countries Clinical Trials Partnership (EDCTP) Senior Fellowship (project number TA.11.40200.025).

Conflicts of interest. None.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

- Amer A and Amer ME (2002) Enhanced monocyte tissue factor expression in hepatosplenic schistosomiasis. *Blood Coagulation & Fibrinolysis* **13**, 43–47.
- Ateba Ngoa U, Zinsou JF, Kassa RKF, *et al.* (2014) Assessment of the effect of *Schistosoma haematobium* co infection on malaria parasites and immune responses in rural populations in Gabon: Study protocol. *SpringerPlus* **3**, 388.

- Buchanan GR, Holtkamp CA and Levy EN** (1981) Racial differences in ristocetin-induced platelet aggregation. *British Journal of Haematology* **49**, 455–464.
- Bustinduy AL, Sutherland LJ, Chang-Cojulun A, et al.** (2015) Age-stratified profiles of serum IL-6, IL-10, and TNF- α cytokines among Kenyan children with *Schistosoma haematobium*, *Plasmodium falciparum*, and other Chronic parasitic co-infections. *The American Journal of Tropical Medicine and Hygiene* **92**, 945–951.
- Cheever AW, Kamel IA, Elwi AM, Mosimann JE and Danner R** (1977) *Schistosoma mansoni* and *S. haematobium* infections in Egypt. II. Quantitative parasitological findings at necropsy. *The American Journal of Tropical Medicine and Hygiene* **26**, 702–716.
- Colley DG, Bustinduy AL, Secor WE and King CH** (2014) Human schistosomiasis. *Lancet* **383**, 2253–2264.
- Conway DSG, Pearce LA, Chin BSP, Hart RG and Lip GYH** (2003) Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. *Circulation* **107**, 3141–3145.
- Correia MCB, Domingues ALC, Lacerda HR, et al.** (2009) Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **103**, 1053–1058.
- Corstjens PLAM, De Dood CJ, Kornelis D, et al.** (2014) Tools for diagnosis, monitoring and screening of *Schistosoma* infections utilizing lateral-flow based assays and upconverting phosphor labels. *Parasitology* **141**, 1841–1855.
- Dupuy E, Fleming AF and Caen JP** (1978) Platelet function, factor VIII, fibrinogen, and fibrinolysis in Nigerians and Europeans in relation to atheroma and thrombosis. *Journal of Clinical Pathology* **31**, 1094–1101.
- File S** (1995) Interaction of schistosome eggs with vascular endothelium. *The Journal of Parasitology* **81**, 234–238.
- Flood VH, Gill JC, Morateck PA, et al.** (2010) Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. *Blood* **116**, 280–286.
- Hulstein JJJ, de Groot PG, Silence K, Veyradier A, Fijnheer R and Lenting PJ** (2005) A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. *Blood* **106**, 3035–3042.
- Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K and Nishizawa Y** (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. *Circulation* **106**, 1192–1194.
- Kokame K, Nobe Y, Kokubo Y, Okayama A and Miyata T** (2005) FRET-VWF73, a first fluorogenic substrate for ADAMTS13 assay. *British Journal of Haematology* **129**, 93–100.
- Lip GY and Blann A** (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? *Cardiovascular Research* **34**, 255–265.
- Mebius MM, van Genderen PJJ, Urbanus RT, Tielens AGM, de Groot PG and van Hellemond JJ** (2013) Interference with the host haemostatic system by schistosomes. *PLoS Pathogens* **9**, e1003781.
- Mwatha JK, Kimani G, Kamau T, et al.** (1998) High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni. *Journal of Immunology* **160**, 1992–1999.
- Silva CL, Morel N and Noël F** (1998) Portal veins of mice infected with *Schistosoma mansoni* exhibit an increased reactivity to 5-hydroxytryptamine. *Memorias Do Instituto Oswaldo Cruz* **93**(Suppl 1), 153–155.
- Steinmann P, Keiser J, Bos R, Tanner M and Utzinger J** (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *The Lancet Infectious Diseases* **6**, 411–425.
- Tanabe M** (2003) Haemostatic abnormalities in hepatosplenic schistosomiasis mansoni. *Parasitology International* **52**, 351–359.
- Zannettino ACW, Holding CA, Diamond P, et al.** (2005) Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. *Journal of Cellular Physiology* **204**, 714–723.